Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care

Report of 18 cases

Giulia Schillani, Maria Anna Capozzo, Daniel Era, Maurizio De Vanna, Luigi Grassi, Maria Anna Conte, Tullio Giraldi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aims and background. In palliative care, few data are available on the diagnosis and treatment ofmood disorders and of difficulties ofmental adaptation to cancer for patients in the advanced phases of the disease. SSRI antidepressants are the treatment of choice; the 5-HTTLPR genetic polymorphism of the serotonin transporter (SERT) has been shown in psychiatry to significantly determine the therapeutic response and the incidence of adverse effects. The aim of the present investigation has been therefore to examine the effects of the SSRI antidepressant escitalopram, also considering 5-HTTLPR, on depression, anxiety andmental adaptation to cancer in palliative care. Methods and study design. Eighteen consecutive depressed patients with different forms of advanced cancer admitted to the Hospice Ass 6 of S. Vito al Tagliamento (Pordenone, Italy) were genotyped for the "s" and "l" variants of 5-HTTLPR and were treated with escitalopram. Their response after two weeks of treatment was psychometrically evaluated. Results. Treatment with escitalopram significantly decreased anxiety scores on the Hospital Anxiety and Depression Scale (HADS) (P = 0.006) as well as anxious preoccupation (P = 0.007) and hopelessness-helplessness (P = 0.017) scores on the Mini Mental Adjustment to Cancer (Mini-MAC) scale. When patients were stratified by SERT genotype, HADS anxiety was significantly decreased in patients carrying the "s/s" and "s/l" variants (P = 0.024), whereas those with an "l/l" genotype displayed a significant reduction of Mini-MAC anxious preoccupation (P = 0.018). Conclusions. The results of this study indicate that the use of SSRI antidepressants is effective in the palliative care of cancer patients, and their action affects not only depression but also the patients' mental adaptation to the disease. These results encourage further examination of these drugs in a larger cohort of patients. The significant contribution of pharmacogenetics indicates the possibility of personalized treatment with SSRIs in palliative care.

Original languageEnglish
Pages (from-to)358-361
Number of pages4
JournalTumori
Volume97
Issue number3
DOIs
Publication statusPublished - May 2011

Fingerprint

Citalopram
Pharmacogenetics
Palliative Care
Anxiety
Depression
Antidepressive Agents
Social Adjustment
Neoplasms
Serotonin Plasma Membrane Transport Proteins
Therapeutics
Genotype
Hospices
Equidae
Mentally Ill Persons
Genetic Polymorphisms
Italy
Psychiatry
Incidence
Pharmaceutical Preparations

Keywords

  • Antidepressant drugs
  • Mental adaptation to cancer
  • Palliative care
  • Pharmacogenetics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Schillani, G., Capozzo, M. A., Era, D., De Vanna, M., Grassi, L., Conte, M. A., & Giraldi, T. (2011). Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care: Report of 18 cases. Tumori, 97(3), 358-361. https://doi.org/10.1700/912.10034

Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care : Report of 18 cases. / Schillani, Giulia; Capozzo, Maria Anna; Era, Daniel; De Vanna, Maurizio; Grassi, Luigi; Conte, Maria Anna; Giraldi, Tullio.

In: Tumori, Vol. 97, No. 3, 05.2011, p. 358-361.

Research output: Contribution to journalArticle

Schillani, G, Capozzo, MA, Era, D, De Vanna, M, Grassi, L, Conte, MA & Giraldi, T 2011, 'Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care: Report of 18 cases', Tumori, vol. 97, no. 3, pp. 358-361. https://doi.org/10.1700/912.10034
Schillani G, Capozzo MA, Era D, De Vanna M, Grassi L, Conte MA et al. Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care: Report of 18 cases. Tumori. 2011 May;97(3):358-361. https://doi.org/10.1700/912.10034
Schillani, Giulia ; Capozzo, Maria Anna ; Era, Daniel ; De Vanna, Maurizio ; Grassi, Luigi ; Conte, Maria Anna ; Giraldi, Tullio. / Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care : Report of 18 cases. In: Tumori. 2011 ; Vol. 97, No. 3. pp. 358-361.
@article{3cdf626d2aeb452db235cba38a7f7856,
title = "Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care: Report of 18 cases",
abstract = "Aims and background. In palliative care, few data are available on the diagnosis and treatment ofmood disorders and of difficulties ofmental adaptation to cancer for patients in the advanced phases of the disease. SSRI antidepressants are the treatment of choice; the 5-HTTLPR genetic polymorphism of the serotonin transporter (SERT) has been shown in psychiatry to significantly determine the therapeutic response and the incidence of adverse effects. The aim of the present investigation has been therefore to examine the effects of the SSRI antidepressant escitalopram, also considering 5-HTTLPR, on depression, anxiety andmental adaptation to cancer in palliative care. Methods and study design. Eighteen consecutive depressed patients with different forms of advanced cancer admitted to the Hospice Ass 6 of S. Vito al Tagliamento (Pordenone, Italy) were genotyped for the {"}s{"} and {"}l{"} variants of 5-HTTLPR and were treated with escitalopram. Their response after two weeks of treatment was psychometrically evaluated. Results. Treatment with escitalopram significantly decreased anxiety scores on the Hospital Anxiety and Depression Scale (HADS) (P = 0.006) as well as anxious preoccupation (P = 0.007) and hopelessness-helplessness (P = 0.017) scores on the Mini Mental Adjustment to Cancer (Mini-MAC) scale. When patients were stratified by SERT genotype, HADS anxiety was significantly decreased in patients carrying the {"}s/s{"} and {"}s/l{"} variants (P = 0.024), whereas those with an {"}l/l{"} genotype displayed a significant reduction of Mini-MAC anxious preoccupation (P = 0.018). Conclusions. The results of this study indicate that the use of SSRI antidepressants is effective in the palliative care of cancer patients, and their action affects not only depression but also the patients' mental adaptation to the disease. These results encourage further examination of these drugs in a larger cohort of patients. The significant contribution of pharmacogenetics indicates the possibility of personalized treatment with SSRIs in palliative care.",
keywords = "Antidepressant drugs, Mental adaptation to cancer, Palliative care, Pharmacogenetics",
author = "Giulia Schillani and Capozzo, {Maria Anna} and Daniel Era and {De Vanna}, Maurizio and Luigi Grassi and Conte, {Maria Anna} and Tullio Giraldi",
year = "2011",
month = "5",
doi = "10.1700/912.10034",
language = "English",
volume = "97",
pages = "358--361",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care

T2 - Report of 18 cases

AU - Schillani, Giulia

AU - Capozzo, Maria Anna

AU - Era, Daniel

AU - De Vanna, Maurizio

AU - Grassi, Luigi

AU - Conte, Maria Anna

AU - Giraldi, Tullio

PY - 2011/5

Y1 - 2011/5

N2 - Aims and background. In palliative care, few data are available on the diagnosis and treatment ofmood disorders and of difficulties ofmental adaptation to cancer for patients in the advanced phases of the disease. SSRI antidepressants are the treatment of choice; the 5-HTTLPR genetic polymorphism of the serotonin transporter (SERT) has been shown in psychiatry to significantly determine the therapeutic response and the incidence of adverse effects. The aim of the present investigation has been therefore to examine the effects of the SSRI antidepressant escitalopram, also considering 5-HTTLPR, on depression, anxiety andmental adaptation to cancer in palliative care. Methods and study design. Eighteen consecutive depressed patients with different forms of advanced cancer admitted to the Hospice Ass 6 of S. Vito al Tagliamento (Pordenone, Italy) were genotyped for the "s" and "l" variants of 5-HTTLPR and were treated with escitalopram. Their response after two weeks of treatment was psychometrically evaluated. Results. Treatment with escitalopram significantly decreased anxiety scores on the Hospital Anxiety and Depression Scale (HADS) (P = 0.006) as well as anxious preoccupation (P = 0.007) and hopelessness-helplessness (P = 0.017) scores on the Mini Mental Adjustment to Cancer (Mini-MAC) scale. When patients were stratified by SERT genotype, HADS anxiety was significantly decreased in patients carrying the "s/s" and "s/l" variants (P = 0.024), whereas those with an "l/l" genotype displayed a significant reduction of Mini-MAC anxious preoccupation (P = 0.018). Conclusions. The results of this study indicate that the use of SSRI antidepressants is effective in the palliative care of cancer patients, and their action affects not only depression but also the patients' mental adaptation to the disease. These results encourage further examination of these drugs in a larger cohort of patients. The significant contribution of pharmacogenetics indicates the possibility of personalized treatment with SSRIs in palliative care.

AB - Aims and background. In palliative care, few data are available on the diagnosis and treatment ofmood disorders and of difficulties ofmental adaptation to cancer for patients in the advanced phases of the disease. SSRI antidepressants are the treatment of choice; the 5-HTTLPR genetic polymorphism of the serotonin transporter (SERT) has been shown in psychiatry to significantly determine the therapeutic response and the incidence of adverse effects. The aim of the present investigation has been therefore to examine the effects of the SSRI antidepressant escitalopram, also considering 5-HTTLPR, on depression, anxiety andmental adaptation to cancer in palliative care. Methods and study design. Eighteen consecutive depressed patients with different forms of advanced cancer admitted to the Hospice Ass 6 of S. Vito al Tagliamento (Pordenone, Italy) were genotyped for the "s" and "l" variants of 5-HTTLPR and were treated with escitalopram. Their response after two weeks of treatment was psychometrically evaluated. Results. Treatment with escitalopram significantly decreased anxiety scores on the Hospital Anxiety and Depression Scale (HADS) (P = 0.006) as well as anxious preoccupation (P = 0.007) and hopelessness-helplessness (P = 0.017) scores on the Mini Mental Adjustment to Cancer (Mini-MAC) scale. When patients were stratified by SERT genotype, HADS anxiety was significantly decreased in patients carrying the "s/s" and "s/l" variants (P = 0.024), whereas those with an "l/l" genotype displayed a significant reduction of Mini-MAC anxious preoccupation (P = 0.018). Conclusions. The results of this study indicate that the use of SSRI antidepressants is effective in the palliative care of cancer patients, and their action affects not only depression but also the patients' mental adaptation to the disease. These results encourage further examination of these drugs in a larger cohort of patients. The significant contribution of pharmacogenetics indicates the possibility of personalized treatment with SSRIs in palliative care.

KW - Antidepressant drugs

KW - Mental adaptation to cancer

KW - Palliative care

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=79960869990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960869990&partnerID=8YFLogxK

U2 - 10.1700/912.10034

DO - 10.1700/912.10034

M3 - Article

VL - 97

SP - 358

EP - 361

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 3

ER -